Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision dosing of infliximab maintenance therapy in inflammatory bowel disease
NL-OMON42154Phase 4Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of infliximab in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Proportion of patients with sustained clinical remission. Started May 2015; status: active, not recruiting.
02
Drugs
infliximab
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on NL-OMON42154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42154.